Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
Level 4, 100 Albert Road
South Melbourne
MelbourneVIC3205
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.40 | 16.50 | -0.19% |
| CAC 40 | 7,605.45 | 50.67 | -0.66% |
| DAX 40 | 23,234.86 | 82.95 | -0.36% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,821.38 | 22.09 | -0.25% |
| HKSE | 23,237.74 | 472.95 | -1.99% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,488.34 | 396.81 | -1.02% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,523.70 | 7.50 | -0.09% |
| SSE Composite Index | 3,362.11 | 26.70 | -0.79% |